Cochrane · systematic review · CD008117
Pharmacological interventions for hypertension in children
Chaturvedi, S, Lipszyc, DH, Licht, C, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
HypertensionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
23
current version
GRADE rated
22
No studies
1
Included studies
NR
No studies 1 · 4.3%Ungraded 0 · 0%Very low 20 · 87%Low 2 · 8.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antihypertensive drug class compared to placebo for hypertension in children: systolic blood pressure reduction
Population: children (from 1 to 18 years of age) with hypertension from primary or secondary causes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Angiotensin receptor blocker (any dose) Mean duration of 4 weeks Antihypertensive drug class vs placebo | no estimate extracted | 1 study · 240 participants | Very low |
Beta‐blocker (any dose) Mean duration of 4 weeks Antihypertensive drug class vs placebo | no estimate extracted | 1 study · 140 participants | Very low |
Calcium channel blocker (any dose) Mean duration of 3 weeks Antihypertensive drug class vs placebo | no estimate extracted | 1 study · 133 participants | Very low |
Beta‐blocker/thiazide combination (any dose) Mean duration of 10 weeks Antihypertensive drug class vs placebo | no estimate extracted | 1 study · 94 participants | Very low |
Antihypertensive drug class compared to placebo for hypertension in children: diastolic blood pressure reduction
Population: children (from 1 to 18 years of age) with hypertension from primary or secondary causes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Angiotensin receptor blocker (any dose) Mean duration of 4 weeks Antihypertensive drug class vs placebo | no estimate extracted | 1 study · 240 participants | Very low |
Beta‐blocker (any dose) Mean duration of 4 weeks Antihypertensive drug class vs placebo | no estimate extracted | 1 study · 140 participants | Very low |
Calcium channel blocker (any dose) Mean duration of 3 weeks Antihypertensive drug class vs placebo | no estimate extracted | 1 study · 133 participants | Very low |
Beta‐blocker/thiazide combination (any dose) Mean duration of 10 weeks Antihypertensive drug class vs placebo | no estimate extracted | 1 study · 94 participants | Very low |
Angiotensin receptor blocker for hypertension in children: dose response in systolic blood pressure
Population: children (from 1 to 18 years of age) with hypertension from primary or secondary causes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Angiotensin receptor blocker (high‐ versus low‐dose) | no estimate extracted | 5 studies · 418 participants | Low |
Angiotensin receptor blocker (high‐ versus medium‐dose) | no estimate extracted | 3 studies · 237 participants | Very low |
Angiotensin receptor blocker (medium‐ versus low‐dose) | no estimate extracted | 3 studies · 160 participants | Very low |
Angiotensin receptor blocker for hypertension in children: dose response in diastolic blood pressure
Population: children (from 1 to 18 years of age) with hypertension from primary or secondary causes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
High‐ versus low‐dose | no estimate extracted | 5 studies · 418 participants | Low |
High‐ versus medium‐dose | no estimate extracted | 3 studies · 237 participants | Very low |
Medium‐ versus low‐dose | no estimate extracted | 3 studies · 160 participants | Very low |
Angiotensin converting enzyme inhibitor for hypertension in children: dose response in systolic blood pressure
Population: children (from 1 to 18 years of age) with hypertension from primary or secondary causes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Angiotensin‐converting enzyme inhibitor | no estimate extracted | NR | No studies |
High‐ versus low‐dose | no estimate extracted | 3 studies · 187 participants | Very low |
High‐ versus medium‐ dose | no estimate extracted | 3 studies · 187 participants | Very low |
Medium‐ versus low‐dose | no estimate extracted | 3 studies · 139 participants | Very low |
Angiotensin converting enzyme inhibitor for hypertension in children: dose response in diastolic blood pressure
Population: children (from 1 to 18 years of age) with hypertension from primary or secondary causes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
High‐ versus low‐dose | no estimate extracted | 3 studies · 187 participants | Very low |
High‐ versus medium‐dose | no estimate extracted | 3 studies · 187 participants | Very low |
Medium‐ versus low‐dose | no estimate extracted | 3 studies · 139 participants | Very low |
Calcium channel blocker for hypertension in children: dose response in systolic and diastolic blood pressure
Population: children (from 1 to 18 years of age) with hypertension from primary or secondary causes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
High vs low dose Systolic blood pressure | no estimate extracted | 1 study · 141 participants | Very low |
High vs low dose Diastolic blood pressure | no estimate extracted | 1 study · 141 participants | Very low |